TherapeuticsMD Inc (TXMD) Upgraded to Hold at Zacks Investment Research

TherapeuticsMD Inc (NASDAQ:TXMD) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report released on Thursday.

According to Zacks, “TherapeuticsMD, Inc. is a specialty pharmaceutical company focused on creating branded prescription, generic prescription and over-the-counter products targeted exclusively for women. It is developing three advanced hormone replacement products designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies. TherapeuticsMD, Inc. is based in Boca Raton, Florida. “

Several other brokerages have also recently issued reports on TXMD. Oppenheimer Holdings, Inc. restated an “outperform” rating and set a $10.00 price objective on shares of TherapeuticsMD in a research note on Friday, July 21st. Deutsche Bank AG began coverage on TherapeuticsMD in a research note on Friday, July 21st. They set a “buy” rating and a $10.00 price objective on the stock. Cantor Fitzgerald restated an “overweight” rating and set a $33.00 price objective on shares of TherapeuticsMD in a research note on Friday, July 21st. Cowen and Company restated an “outperform” rating and set a $13.00 price objective on shares of TherapeuticsMD in a research note on Monday, July 17th. Finally, Noble Financial reiterated a “buy” rating on shares of TherapeuticsMD in a research report on Friday, August 4th. One investment analyst has rated the stock with a hold rating and eight have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $16.14.

TherapeuticsMD (NASDAQ:TXMD) opened at 5.57 on Thursday. The firm has a 50 day moving average price of $5.44 and a 200 day moving average price of $5.52. The stock’s market capitalization is $1.14 billion. TherapeuticsMD has a 52 week low of $3.50 and a 52 week high of $8.30.

TherapeuticsMD (NASDAQ:TXMD) last announced its quarterly earnings data on Thursday, August 3rd. The company reported ($0.10) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.11) by $0.01. TherapeuticsMD had a negative return on equity of 71.36% and a negative net margin of 530.84%. The firm had revenue of $4.25 million for the quarter, compared to analysts’ expectations of $4.91 million. During the same quarter in the prior year, the firm posted ($0.11) earnings per share. TherapeuticsMD’s revenue for the quarter was down 3.4% compared to the same quarter last year. Equities research analysts predict that TherapeuticsMD will post ($0.45) earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally published by Ticker Report and is owned by of Ticker Report. If you are accessing this piece of content on another website, it was illegally copied and republished in violation of US & international copyright & trademark laws. The original version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/2797571/therapeuticsmd-inc-txmd-upgraded-to-hold-at-zacks-investment-research.html.

Several hedge funds have recently made changes to their positions in the company. JPMorgan Chase & Co. boosted its stake in shares of TherapeuticsMD by 14.3% in the second quarter. JPMorgan Chase & Co. now owns 15,687,509 shares of the company’s stock worth $82,674,000 after buying an additional 1,961,656 shares during the last quarter. Oppenheimer & Co. Inc. boosted its stake in shares of TherapeuticsMD by 72.9% in the second quarter. Oppenheimer & Co. Inc. now owns 71,706 shares of the company’s stock worth $378,000 after buying an additional 30,240 shares during the last quarter. Principal Financial Group Inc. boosted its stake in shares of TherapeuticsMD by 3.9% in the second quarter. Principal Financial Group Inc. now owns 21,711 shares of the company’s stock worth $114,000 after buying an additional 818 shares during the last quarter. Greenwood Capital Associates LLC boosted its stake in shares of TherapeuticsMD by 173.2% in the second quarter. Greenwood Capital Associates LLC now owns 55,486 shares of the company’s stock worth $292,000 after buying an additional 35,177 shares during the last quarter. Finally, Columbus Circle Investors boosted its stake in shares of TherapeuticsMD by 10.6% in the second quarter. Columbus Circle Investors now owns 2,134,216 shares of the company’s stock worth $11,247,000 after buying an additional 203,768 shares during the last quarter.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.

Get a free copy of the Zacks research report on TherapeuticsMD (TXMD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for TherapeuticsMD (NASDAQ:TXMD)

Receive News & Ratings for TherapeuticsMD Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2017 Ticker Report. Google+.